Gene therapy is moving from the lab bench to the front lines of modern medicine — and Eli Lilly is wasting no time securing its position. The pharmaceutical giant has struck a deal with biotech firm MeiraGTx, gaining access to breakthrough technologies for treating rare genetic vision disorders. The agreement includes $75 million upfront and up to $400 million in milestone payments, signaling Lilly’s intent to lead in one of medicine’s most transformative fields.

Beyond the financials, this move reflects a broader shift in healthcare: from treating symptoms to repairing the root cause of disease. With the gene therapy market projected to exceed $8 billion within a decade, Lilly isn’t just chasing revenue — it’s positioning itself at the forefront of a paradigm where a single treatment could mean a lifetime cure.

A new horizon in medicine: gene therapy for vision

Gene therapy is considered one of the most promising directions in modern medicine. Unlike traditional medicines, it does not…